MA56119A - Procédés et réactifs pour réduire les interférences de médicaments se liant au cd47 dans des dosages sérologiques - Google Patents
Procédés et réactifs pour réduire les interférences de médicaments se liant au cd47 dans des dosages sérologiquesInfo
- Publication number
- MA56119A MA56119A MA056119A MA56119A MA56119A MA 56119 A MA56119 A MA 56119A MA 056119 A MA056119 A MA 056119A MA 56119 A MA56119 A MA 56119A MA 56119 A MA56119 A MA 56119A
- Authority
- MA
- Morocco
- Prior art keywords
- reagents
- reducing
- methods
- binding drug
- serological assays
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/34—Post-translational modifications [PTMs] in chemical analysis of biological material addition of amino acid(s), e.g. arginylation, (poly-)glutamylation, (poly-)glycylation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962858871P | 2019-06-07 | 2019-06-07 | |
| US201962934395P | 2019-11-12 | 2019-11-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56119A true MA56119A (fr) | 2022-04-13 |
Family
ID=71899853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA056119A MA56119A (fr) | 2019-06-07 | 2020-06-05 | Procédés et réactifs pour réduire les interférences de médicaments se liant au cd47 dans des dosages sérologiques |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20200400662A1 (fr) |
| EP (1) | EP3980747A1 (fr) |
| JP (1) | JP7561775B2 (fr) |
| CN (1) | CN114206912B (fr) |
| MA (1) | MA56119A (fr) |
| WO (1) | WO2020247820A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2740672C2 (ru) | 2015-08-07 | 2021-01-19 | ЭйЭлЭкс Онколоджи Инк. | Конструкции, имеющие sirp-альфа домен или его вариант |
| US20200140565A1 (en) | 2016-10-20 | 2020-05-07 | I-Mab | Novel cd47 monoclonal antibodies and uses thereof |
| CA3141130A1 (fr) | 2019-05-31 | 2020-12-03 | ALX Oncology Inc. | Methodes de traitement du cancer avec une proteine de fusion sirpalpha-fc en association avec un inhibiteur de point de controle immunitaire |
| WO2021108693A1 (fr) | 2019-11-27 | 2021-06-03 | ALX Oncology Inc. | Polythérapies pour le traitement du cancer |
| JP2023528341A (ja) | 2020-06-01 | 2023-07-04 | エーエルエックス オンコロジー インコーポレイテッド | 低メチル化剤を含むがんを治療するための併用療法 |
| CN116261662B (zh) * | 2020-10-14 | 2024-05-31 | 天境生物科技(上海)有限公司 | 用于减轻输血前测定中治疗性抗cd47抗体的干扰的方法 |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
| WO2024105180A1 (fr) | 2022-11-16 | 2024-05-23 | Boehringer Ingelheim International Gmbh | Biomarqueurs d'efficacité prédictive pour anticorps anti-sirpa |
| CN116380580A (zh) * | 2023-03-15 | 2023-07-04 | 中国人民解放军空军军医大学 | 一种血浆检测前处理方法 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2111869A1 (fr) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions et procédés pour renforcer le système immunitaire |
| KR20120107122A (ko) | 2009-12-22 | 2012-09-28 | 노파르티스 아게 | 치료법에서 사용하기 위한 ４가 ｃｄ４７―항체 불변 영역 융합 단백질 |
| MX2013014789A (es) | 2011-06-16 | 2014-01-20 | Novartis Ag | Proteinas solubles para utilizarse como productos terapeuticos. |
| EP3766511A1 (fr) | 2012-01-17 | 2021-01-20 | The Board of Trustees of the Leland Stanford Junior University | Réactifs sirp-alpha de haute affinité |
| US20140140989A1 (en) | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
| ME03512B (fr) | 2012-02-06 | 2020-04-20 | Inhibrx Inc | Anticorps anti-cd47 et leurs méthodes d'utilisation |
| RU2693078C2 (ru) | 2012-12-03 | 2019-07-01 | Новиммун С.А. | Анти-cd47 антитела и способы их применения |
| US9221908B2 (en) | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
| MX2015007446A (es) | 2012-12-12 | 2015-12-07 | Vasculox Inc | Anticuerpos terapeuticos para cd47. |
| ME03550B (fr) | 2012-12-17 | 2020-07-20 | Trillium Therapeutics Inc | Traitement de cellules tumorales à cd47+ avec des fusions sirp alpha/fc |
| SG10201706383XA (en) | 2013-02-06 | 2017-09-28 | Inhibrx Lp | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof |
| CN105189556A (zh) * | 2013-03-15 | 2015-12-23 | 小利兰·斯坦福大学托管委员会 | 用于实现治疗有效剂量的抗cd47剂的方法 |
| WO2016023040A1 (fr) | 2014-08-08 | 2016-02-11 | Alexo Therapeutics International | Constructions de variant sirp-alpha et leurs utilisations |
| EP3012271A1 (fr) | 2014-10-24 | 2016-04-27 | Effimune | Procédé et compositions pour induire la différenciation de cellule suppressives dérivées de myéloïde pour traiter le cancer et les maladies infectieuses |
| WO2016081423A1 (fr) | 2014-11-18 | 2016-05-26 | Janssen Pharmaceutica Nv | Anticorps anti-cd47, procédés et utilisations |
| HK1245154A1 (zh) | 2014-12-30 | 2018-08-24 | 细胞基因公司 | 抗cd47抗体及其用途 |
| ES2752054T3 (es) | 2015-03-31 | 2020-04-02 | Novimmune Sa | Método para optimizar el ensamble y producción de complejos de proteínas heteromultiméricas |
| CN106146670B (zh) | 2015-04-24 | 2019-01-15 | 宜明昂科生物医药技术（上海）有限公司 | 一种新的重组双功能融合蛋白及其制备和应用 |
| WO2016179399A1 (fr) | 2015-05-06 | 2016-11-10 | The Board Of Trustees Of The Leland Stanford Junior University | Analogues du cd47 à haute affinité |
| DK3298043T3 (da) | 2015-05-18 | 2021-02-15 | Ab Initio Biotherapeutics Inc | SIRP-polypeptidsammensætninger og fremgangsmåder til anvendelse |
| RU2740672C2 (ru) | 2015-08-07 | 2021-01-19 | ЭйЭлЭкс Онколоджи Инк. | Конструкции, имеющие sirp-альфа домен или его вариант |
| CN116425875A (zh) | 2015-09-18 | 2023-07-14 | 安驰肿瘤公司 | 治疗性cd47抗体 |
| US9650441B2 (en) | 2015-09-21 | 2017-05-16 | Erasmus University Medical Center | Anti-CD47 antibodies and methods of use |
| DK4186927T3 (da) | 2015-10-21 | 2025-06-10 | Ose Immunotherapeutics | Fremgangsmåder og sammensætninger til at ændre makrofagers polarisering til pro-inflammatoriske celler til behandling af kræft |
| CA3011097C (fr) | 2016-01-11 | 2022-12-20 | Forty Seven, Inc. | Anticorps monoclonaux anti-cd47 humanises, de souris ou chimeriques |
| WO2017177333A1 (fr) | 2016-04-15 | 2017-10-19 | Trillium Therapeutics Inc. | Stimulation des macrophages en thérapie par blocage de cd47 |
| WO2017196793A1 (fr) | 2016-05-09 | 2017-11-16 | Celgene Corporation | Anticorps cd47 et leurs méthodes d'utilisation |
| JP7120989B2 (ja) | 2016-07-06 | 2022-08-17 | セルジーン コーポレイション | 低免疫原性を有する抗体及びその使用 |
| EP3493845A4 (fr) | 2016-08-03 | 2020-04-15 | The Board of Trustees of the Leland Stanford Junior University | L'interruption de l'engagement du récepteur fc sur les macrophages améliore l'efficacité de la thérapie par anticorps anti-sirpalpha |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| US20200140565A1 (en) | 2016-10-20 | 2020-05-07 | I-Mab | Novel cd47 monoclonal antibodies and uses thereof |
| EP3529276A4 (fr) | 2016-10-21 | 2020-06-17 | Arch Oncology, Inc. | Anticorps cd47 thérapeutiques |
| CA3042581A1 (fr) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Amelioration de la therapie de blocage des cd47 par des inhibiteurs du proteasome |
| WO2018081898A1 (fr) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Améliorations de la thérapie de blocage de cd47 par des inhibiteurs de hdac |
| TW201819413A (zh) | 2016-11-28 | 2018-06-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｃｄ４７抗體、其抗原結合片段及其醫藥用途 |
| CN110325549B (zh) | 2016-12-09 | 2024-03-08 | 艾利妥 | 抗SIRPα抗体及其使用方法 |
| PT3443010T (pt) | 2017-02-17 | 2024-10-21 | Ose Immunotherapeutics | Novos anticorpos anti-sirpa e suas aplicações terapêuticas |
| CN110300764A (zh) | 2017-02-17 | 2019-10-01 | Ose免疫疗法 | 抗SIRPg抗体的新用途 |
| WO2018175790A1 (fr) | 2017-03-22 | 2018-09-27 | Arch Oncology, Inc. | Polythérapie pour le traitement de cancers solides et hématologiques |
| EP3601351A1 (fr) | 2017-03-27 | 2020-02-05 | Celgene Corporation | Procédés et compositions pour la réduction d'immunogénicité |
| CA3057718A1 (fr) | 2017-03-28 | 2018-10-04 | Trillium Therapeutics Inc. | Therapie par blocage de cd47 |
| JP7160833B2 (ja) | 2017-04-13 | 2022-10-25 | サイロパ ビー．ブイ． | 抗ｓｉｒｐアルファ抗体 |
| PT3625259T (pt) | 2017-05-16 | 2024-07-04 | Synthon Biopharmaceuticals Bv | Anticorpos anti-sirpalfa |
| WO2018236904A1 (fr) | 2017-06-19 | 2018-12-27 | Surface Oncology, Inc. | Combinaison d'anticorps anti-cd47 et d'agents induisant la mort cellulaire, et leurs utilisations |
| ES2976558T3 (es) | 2017-06-21 | 2024-08-05 | The Board Of Trustees Of The Leland Stanfordjunior Univ | Parámetros de dosificación para terapias de direccionamiento de CD47 en neoplasias hematológicas |
| EP3658589B1 (fr) | 2017-07-26 | 2023-09-27 | Forty Seven, Inc. | Anticorps anti-sirp-alpha et méthodes associées |
| CN109422811A (zh) | 2017-08-29 | 2019-03-05 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
-
2020
- 2020-06-05 EP EP20750429.1A patent/EP3980747A1/fr active Pending
- 2020-06-05 CN CN202080041810.5A patent/CN114206912B/zh active Active
- 2020-06-05 MA MA056119A patent/MA56119A/fr unknown
- 2020-06-05 WO PCT/US2020/036425 patent/WO2020247820A1/fr not_active Ceased
- 2020-06-05 JP JP2021572418A patent/JP7561775B2/ja active Active
- 2020-06-05 US US16/894,468 patent/US20200400662A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20200400662A1 (en) | 2020-12-24 |
| EP3980747A1 (fr) | 2022-04-13 |
| JP2022535286A (ja) | 2022-08-05 |
| JP7561775B2 (ja) | 2024-10-04 |
| CN114206912B (zh) | 2025-02-11 |
| WO2020247820A1 (fr) | 2020-12-10 |
| CN114206912A (zh) | 2022-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2438442A4 (fr) | Procédés et dosages pour mesurer p95 et/ou p95 dans un échantillon et anticorps spécifiques de p95 | |
| EP3665187A4 (fr) | Procédés de dosage pour la détection améliorée d'analytes | |
| BRPI0819211A2 (pt) | Anticorpos de anti-hepcidina e usos dos mesmos, polinucleotídeo, vetor de expressão recombinante, processo para produzir um anticorpo, composição farmacêutica, imunoensaio e kit para a realização do mesmo | |
| EP2254568A4 (fr) | Procédés et dosages pour détecter et traiter une hypoglycémie | |
| MA53338A (fr) | Dosages pour détecter la neurodégénérescence | |
| EP3781585A4 (fr) | Dosages in vitro sensibles pour des préférences de substrat et de sites d'agents de liaison, de modification et de clivage d'acide nucléique | |
| EP3934684A4 (fr) | Apprentissage automatique dans des dosages de cancers fonctionnels | |
| WO2006122311A3 (fr) | Puce microfluidique | |
| WO2008048300A3 (fr) | Biocapteur de détection pathogène | |
| PT2274335E (pt) | Anticorpos monoclonais capazes de reagirem com diversos subtipos de vírus a da gripe | |
| DK1891447T3 (da) | Totrins laterale flowassayfremgangsmåder og -anordninger | |
| CO6231057A2 (es) | Sensibilidad mejorada de determinacion del perfil de anticuerpos a traves de una colocacion en capas incrementada de anticuerpo reportero | |
| MX2008014293A (es) | Metodos de ensayo sin separacion. | |
| EP2092355A4 (fr) | Ressources de partage dans un système pour éprouver des dispositifs semi-conducteurs | |
| EP3867397A4 (fr) | Procédés et réactifs pour le génotypage efficace de grands nombres d'échantillons par regroupement | |
| BRPI0818437A2 (pt) | Anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menosum dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma | |
| BRPI0818780A2 (pt) | Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos | |
| RU2020129667A (ru) | Способ детектирования молекулы-мишени и набор для использования в этом способе | |
| EP2331969A4 (fr) | Détection de protéines associées au vih dans l'urine | |
| BRPI1005176A2 (pt) | ensaio de insulina, reagente de ensaio de insulina, anticorpo monoclonal, e, método de triar anticorpos monoclonais. | |
| WO2015191546A3 (fr) | Réactifs de détection d'adp-ribose | |
| EP3464598A4 (fr) | Dosages d'analytes basés sur les aptamères | |
| EP3719499A4 (fr) | Procédé de dosage et kit de dosage pour l'antigène s du virus de l'hépatite b | |
| EP3887802A4 (fr) | Procédés et structures pour améliorer l'efficacité de collecte de lumière dans des biocapteurs | |
| EP2367959A4 (fr) | Procédés et réactifs pour raccourcir les temps d'incubation dans des dosages par hybridation |